Gosuranemab fails to meet endpoints in Phase II study in Alzheimer’s disease

The anti-tau antibody failed to meet its primary efficacy endpoint of change from baseline at 78 weeks in patients with mild cognitive impairment due to Alzheimer’s compared to placebo based on the Clinical Dementia Rating Scale-Sum of Boxes.

Source:

Biospace Inc.